At 17.0% CAGR, the Europe Antibody Drug Conjugates Market Is Projected to be Worth US$ 7,947.86 Million by 2030, Says Business Market Insights

According to Business Market Insights' research, the Europe antibody drug conjugates market was valued at US$ 2,263.14 million in 2022 and is expected to reach US$ 7,947.86 million by 2030, registering a CAGR of 17.0% from 2022 to 2030. Rising incidences of cancer cases and growing strategic partnerships to develop antibody drug conjugates are among the critical factors attributed to the Europe antibody drug conjugates market expansion.

Rising cancer incidences are primarily leading to the increasing demand for innovative cancer treatments. As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, there were 19.3 million cancer cases across the globe. Similarly, as per the World Health Organization (WHO) data published in February 2022, ~10 million people have died from cancer. The most commonly seen cancer types were lung, breast, colon and rectum, prostate, and breast. The rising incidences of cancer have raised concerns worldwide. Below is the list of common cancer cases reported worldwide in 2020. 

New Cancer Cases Worldwide, in 2020

Cancer is now a lifestyle disease commonly seen among people with unhealthy food habits and who are physically inactive. Also, the consumption of alcohol and tobacco adds up to the risk of developing cancer. Chronic infectious diseases in low- and middle-income countries can further aggravate the cancer risk factors. According to the WHO data published in February 2022, chronic infectious diseases such as human papillomavirus (HPV), Helicobacter pylori, hepatitis B virus, hepatitis C virus, and Epstein-Barr virus attributed to nearly 18% of the diagnosed in 2018. Also, promising results of ADCs are anticipated to accelerate their demand as an effective cancer treatment and propel the market growth.

On the contrary, high cost of ADCs development and commercialization hampers the growth Europe antibody drug conjugates market.

Based on technology, the Europe antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held 67.9% share of the Europe antibody drug conjugates market in 2022, amassing US$ 1,536.17 million. It is projected to garner US$ 5,327.46 million by 2030 to expand at 16.8% CAGR during 2022–2030.

Based on application, the Europe antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held 57.3% share of the Europe antibody drug conjugates market in 2022, amassing US$ 1,297.53 million. It is projected to garner US$ 4,690.90 million by 2030 to expand at 17.4% CAGR during 2022–2030.

Based on distribution channel, the Europe antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 70.9% share of Europe antibody drug conjugates market in 2022, amassing US$ 1,604.81 million. It is projected to garner US$ 5,771.53 million by 2030 to expand at 17.4% CAGR during 2022–2030.

Based on country, the Europe antibody drug conjugates market is categorized into Germany, France, UK, Italy, Spain, and the Rest of Europe. Germany held 31.7% share of Europe antibody drug conjugates market in 2022, amassing US$ 716.28 million. It is projected to garner US$ 2,658.56 million by 2030 to expand at 17.8% CAGR during 2022–2030.

Key players operating in the Europe antibody drug conjugates market are ADC Therapeutics SA, Pfizer Inc, Hoffmann-La Roche Ltd, ImmunoGen, Inc, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, and Takeda Pharmaceutical Co Ltd, among others. 

• In Mar 2023, Pfizer Inc. and Seagen Inc entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.
• In Sept 2023, Seagen Inc., a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and RemeGen Co., Ltd. have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC. This collaboration leverages Seagen’s world-class expertise and knowledge of ADC development, manufacturing, and commercialization to maximize the potential of disitamab vedotin.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com